PPARγagonists against respiratory syncytial virus infection in vitro study
10.3760/cma.j.issn.1003-9279.2011.06.024
- VernacularTitle:PPARγ激动剂抗呼吸道合胞病毒感染作用的体外研究
- Author:
Chun-Jie WAN
1
;
Lin DONG
;
Jie LIN
;
Xiao-Fang CHEN
Author Information
1. 温州医学院附属育英儿童医院
- Keywords:
PPARγagonists;
Respiratory syncytial virus,human;
Infection
- From:
Chinese Journal of Experimental and Clinical Virology
2011;25(6):480-482
- CountryChina
- Language:Chinese
-
Abstract:
Objective To search the effect of PPARγ agonists for infection of RSV in vitro.Methods The CPE of Hep-2 and A549 cells induced by RSV infection were observed.The effects of 15d-PGJ2 and rosiglitazone on change of CPE of A549 cells induced by RSV infection for 48 h were observed,too.MTT assay was used to detect the rate of viral suppression,and the protective effects of 15d-PGJ2 and rosiglitazone on A549 cells induced by RSV infection for 48 h.Results A549 cells interfered by 15d-PGJ2 (5 -25 μmol/L) and rosiglitazone (10 -50 μmol/L) did not show obvious CPE,MTT assay also showed that the survival rate of A549 cells induced by RSV infection with PPARγ agonists added,was significantly higher than that of RSV infection without PPARγ agonists added,the difference was statistically significant (P ＜ 0.01 ),but comparision between the two drugs showed no statistical significance.The optimal concentrations of 15d-PGJ2 and rosiglitazone were 5 μmol/L and 10 μ mol/L respectively.Conclusions PPARγ agonist can reduce the CPE of A549 cells after RSV infection and improve the survival rate of A549 cells.PPARγ agonist can counteract the infection of RSV in A549 cells.
